Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | BCHE | P06276 | 4/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.51 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038720 | 0.94 | PKM (0.67) | PKMLTA4HMEN1KMT2AACHE | |
| SCHEMBL3039207 | 0.90 | MEN1 (0.59) | PKMLTA4HMEN1KMT2AACHE | |
| SCHEMBL3042578 | 0.89 | MEN1 (0.64) | PKMLTA4HMEN1KMT2AACHE | |
| SCHEMBL14569696 | 0.87 | TSHR (0.66) | PKMLTA4HMEN1KMT2AACHE | |
| SCHEMBL3040571 | 0.85 | MEN1 (0.63) | LTA4HMEN1KMT2AACHEBCHE | |
| SCHEMBL14569771 | 0.84 | TSHR (0.69) | PKMMEN1KMT2AACHEBCHE | |
| SCHEMBL18065785 | 0.83 | PKM (0.52) | PKMLTA4HMEN1KMT2AACHE | |
| Hydrochloric Acid SCHEMBL10375036 | 0.83 | SIGMAR1 (0.55) | LTA4HMEN1KMT2AACHELPAR1 | |
| SCHEMBL20249532 | 0.82 | TSHR (0.63) | LTA4HMEN1KMT2AACHEBCHE | |
| SCHEMBL3043675 | 0.82 | NR4A2 (0.70) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272649-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272649-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | PKM 4171/4885KCNH2 1530/4885LTA4H 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.